Rothschild & Co Downgrades Moderna to Sell, Raises Price Target to $81

Benzinga · 1d ago
Rothschild & Co analyst Simon Baker downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $40 to $81.